
    
      We will enroll 60 female participants in this study. From the population of interest, female
      cancer survivors (or women treated for a related illness) who were treated with TBI prior to
      a SCT, we will enroll 30 participants, 10 from each of the following cancer groups: acute
      lymphoblastic leukemia, acute myeloid leukemia, and chronic myeloid leukemia. We are
      interested in determining the outcomes in adult survivors who have completed their growth by
      the time of study and yet are younger than the age when most women generally begin to develop
      insulin resistance or dyslipidemia in the general population. For this reason, we will enroll
      women who are 18 - 49 years of age at the time of study.
    
  